AbbVie and Pfizer Both Slip as the 2026 Buy Debate Sharpens

AbbVie shares last traded at 255.75, down 1.71%, and Pfizer at 28.43, down 1.32%, as of 19:59 GMT on Sept. 4, 2026, with investors weighing AbbVie's immunology-led pivot away from its former top seller against Pfizer's own growth question.

Two of the biggest names in American pharmaceuticals went into the weekend moving the same direction, and neither was up. AbbVie (ABBV) last changed hands at 255.75, down 1.71% from the prior close of 260.21, while Pfizer (PFE) traded at 28.43, off 1.32% from 28.81, both as of 19:59 GMT on Sept. 4, 2026. It was a soft session broadly: the S&P 500 tracker was at $770.12, down 0.39%, and the Dow 30 tracker at $534.02, down 0.54%, with only the Nasdaq 100 fund green at $719.09, up 0.20%.

The two stocks are being compared because they represent opposite answers to the same question every large drugmaker eventually faces: what happens after the blockbuster runs out of patent protection.

AbbVie's Answer to Losing Its Biggest Drug

The single most important fact about AbbVie's investment case is that it has already been through the event other pharma companies are still bracing for. Its top-selling medicine lost exclusivity — the point at which a drug's patent protection expires and cheaper copies can enter the market — and the company has pivoted to a new generation of immunology leaders to fill the hole, as laid out in a comparison of the two stocks published by Nasdaq Markets.

That matters more than any single quarter's numbers. Loss of exclusivity is usually the moment a pharmaceutical stock de-rates, because the market stops paying for a revenue stream it can see disappearing. A company that has replaced that revenue with newer products of its own — rather than with acquisitions financed by debt, or with cost cuts — has demonstrated something about its research organization that a pipeline chart cannot.

Immunology, the treatment of diseases in which the immune system attacks the body, is also a durable franchise area. Patients on these therapies tend to stay on them, prescribers are concentrated in specialist practices, and the competitive set is small. Building the follow-on leaders inside the same therapeutic area where the company already has commercial relationships is the lower-risk version of a portfolio transition.

Why the Two Share Prices Are Not Comparable

A common mistake in head-to-head stock comparisons is treating the share price itself as information. AbbVie trades at roughly nine times Pfizer's per-share price on the current quotes — an illustrative ratio derived from the two live prices, and one that says nothing whatsoever about which is cheaper. Share count, not share price, determines that. A single AbbVie share represents a different slice of a different business than a single Pfizer share.

What the day's move does tell you is that both were sold, and by similar magnitudes: AbbVie shed about 4.46 points on the session and Pfizer about 0.38, on the live intraday quotes. Both declines were larger in percentage terms than the S&P 500 tracker's 0.39% slip. Healthcare underperforming a mildly negative tape is not a company-specific signal; it is the kind of session where sector rotation, not news, does the work.

Both stocks also traded near the bottom of their intraday ranges. AbbVie's day range ran 255.61 to 258.91, putting the last print close to the low. Pfizer's ran 28.38 to 28.69, likewise near the floor. Closing weak into a Friday is a modest tell about who was in control late in the session, nothing more.

What Actually Separates the Two Cases

Strip out the noise and the choice between these two names comes down to three things an investor can assess independently.

• Pipeline replacement rate. Can new products grow faster than old ones decline? AbbVie's immunology transition is the cleanest available evidence that this is possible at scale in large-cap pharma.
• Income durability. Both companies are widely held for dividends. The relevant test is not the headline yield but whether cash flow from newer products can cover the payout as legacy revenue rolls off.
• What the market has already priced. A stock that has completed a painful transition and a stock that is still expected to grow are valued on different assumptions. The one with lower expectations embedded needs less to go right.

On the last point, the pricing itself is informative. Pfizer's low absolute price and the persistent scepticism attached to post-pandemic pharma revenue suggest a market that is not asking for much. AbbVie's higher multiple of expectation — implied by a share price nine times larger and a franchise the market now believes in again — leaves less room for a stumble in the immunology portfolio.

The Numbers That Would Settle It

Neither company's current dividend yield, forward earnings multiple nor 2026 revenue guidance is established here, and those are the figures that would turn a framework into a verdict. Anyone doing this comparison seriously should pull them from the companies' own filings rather than from a share-price snapshot.

What is worth watching over the coming quarters is narrower and more tractable. For AbbVie: whether the growth rate of the newer immunology products is still accelerating, or has begun to flatten as competitors enter the same indications. A pivot that works for two years and then stalls is a delay, not a solution.

For Pfizer: whether the company can articulate a comparable succession plan for its own maturing products. The AbbVie template is now the benchmark — investors have seen a large-cap drugmaker absorb a loss of exclusivity and come out the other side with a functioning growth engine, which raises the bar for how everyone else explains their next decade.

For both: the macro backdrop. Healthcare is a defensive sector, which means it tends to attract flows when investors turn cautious and lose them when risk appetite returns. The Nasdaq 100 tracker rose 0.20% on a day when both the broad market and the Dow fell — a pattern consistent with money moving toward growth and away from the defensives. One session proves nothing, but if that rotation persists, it will pressure both stocks regardless of what their pipelines are doing.

The honest answer to "which is the better buy" is that they are not the same trade. AbbVie is a bet that a demonstrated transition continues to compound. Pfizer is a bet that low expectations are wrong. Those require different levels of conviction and different holding periods, and an investor who cannot say which one they are making probably should not own either yet.

Key facts

• ABBV last trade: 255.75, -1.71% (as of 19:59 GMT, Sept. 4, 2026)
• PFE last trade: 28.43, -1.32% (as of 19:59 GMT, Sept. 4, 2026)
• AbbVie's pivot: New immunology leaders offsetting loss of exclusivity on its top-selling drug
• Market backdrop: S&P 500 tracker $770.12 (-0.39%); Nasdaq 100 tracker $719.09 (+0.20%)

Frequently asked questions

What does 'loss of exclusivity' mean for a drug company?

Loss of exclusivity is the point at which a medicine's patent protection expires, allowing generic or biosimilar competitors to enter the market at lower prices. Revenue from the affected drug typically falls sharply. AbbVie has already passed this milestone with its top-selling drug and has pivoted to newer immunology products to replace the lost sales.

How did AbbVie and Pfizer shares trade on Sept. 4, 2026?

As of 19:59 GMT on Sept. 4, 2026, AbbVie traded at 255.75, down 1.71% from its prior close of 260.21, with a day range of 255.61 to 258.91. Pfizer traded at 28.43, down 1.32% from 28.81, with a day range of 28.38 to 28.69. Both finished near their session lows.

Does AbbVie's higher share price mean it is more expensive than Pfizer?

No. Share price alone tells you nothing about valuation because it depends on how many shares a company has issued. AbbVie trades at roughly nine times Pfizer's per-share price, but that ratio is meaningless without comparing earnings, cash flow or revenue per share. Valuation requires multiples, not price levels.

Why is immunology considered a durable franchise for drugmakers?

Immunology treats conditions in which the immune system attacks the body. Patients often remain on these therapies long term, prescribing is concentrated among specialists, and the competitive field is relatively narrow. That combination produces recurring revenue and makes it easier for a company to extend existing commercial relationships into newer products in the same area.

How did the broader market perform that session?

It was a mixed and slightly negative tape. The S&P 500 tracker closed the measured period at $770.12, down 0.39%, and the Dow 30 tracker at $534.02, down 0.54%. The Nasdaq 100 tracker was the exception, rising 0.20% to $719.09. Both AbbVie and Pfizer fell by more than the S&P 500 tracker in percentage terms.

What should investors watch next for these two stocks?

For AbbVie, whether growth in its newer immunology products keeps accelerating or flattens as rivals enter the same indications. For Pfizer, whether management can present a credible succession plan for its own maturing products. For both, whether defensive healthcare keeps attracting flows or loses them to growth sectors.

Sources

• AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? — Nasdaq Markets

Photo: cottonbro studio · Pexels Licence — source